Dr. Peter Gottlieb, MD
Endocrinology & Diabetes (Endocrinology, Diabetes & Metabolism Physician)
12605 E 16th Ave
Aurora, CO 80045
Who else practices at this address →
Adams County includes primary care (2% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Rutgers R W Johnson Medical School (Cam/New Bruns/Pisc) (1984)
- Years since graduation
- 42
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 52
Licensed in Colorado since 1994, according to the Colorado Department of Regulatory Agencies. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1984Medical school: Rutgers R W Johnson Medical School (Cam/New Bruns/Pisc)
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Endocrinology, Diabetes & Metabolism Physician primary
CO license 34127 (first issued 1994; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Boulder Community Health Boulder, CO
Medical groups
- University Physicians Incorporated (3,215 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 52
- Services billed
- 234
- Patients’ average age
- 68
| Service | Times | Patients |
|---|---|---|
| Hemoglobin a1c level | 114 | 50 |
| Established patient office or other outpatient visit, 30-39 minutes | 96 | 42 |
| Established patient office or other outpatient visit, 40-54 minutes | 38 | 31 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Levothyroxine Sodium Other prescribers in Aurora, CO | 87 |
| Humalog (insulin lispro) Other prescribers in Aurora, CO | 85 |
| Atorvastatin Calcium Other prescribers in Aurora, CO | 64 |
| Losartan Potassium Other prescribers in Aurora, CO | 58 |
| Ozempic (semaglutide) Other prescribers in Aurora, CO | 43 |
| Rosuvastatin Calcium Other prescribers in Aurora, CO | 42 |
| Lisinopril Other prescribers in Aurora, CO | 41 |
| Metformin Hcl Other prescribers in Aurora, CO | 39 |
| Lantus Solostar (insulin glargine,hum.rec.anlog) Other prescribers in Aurora, CO | 33 |
| Jardiance (empagliflozin) Other prescribers in Aurora, CO | 32 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 8 payments worth $21,617 in total to this clinician.
| Genzyme Corporation | $18,479 |
|---|---|
| Eli Lilly and Company | $1,650 |
| Novo Nordisk As | $1,395 |
| Sanofi-aventis U.S. LLC | $92.54 |
| Consulting Fee | $20,509 |
|---|---|
| Food and Beverage | $780 |
| Travel and Lodging | $328 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Genzyme Corporation Jun 19, 2025 | Consulting Fee | $12,360 |
| Genzyme Corporation Oct 24, 2025 | Consulting Fee | $5,104 |
| Eli Lilly and Company Aug 25, 2025 | Consulting FeeCompany’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH RESEARCH RELATED SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $1,650 |
| Novo Nordisk As Apr 10, 2025 | Consulting FeeCompany’s descriptionThe reported payment reflects the amount provided to a third party employer or institution in connection with services provided by the covered recipient. Novo Nordisk Inc. does not know how much, if any, of this amount was actually received by the covered recipient. | $1,395 |
| Genzyme Corporation Jun 19, 2025 | Travel and Lodging travel to Chicago, IL · in-kind | $328 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $70,197 in research payments for these studies, mostly to the institutions running them.
- Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults and Adolescents on Top of Insulin Therapy (FABULINUS)
Genzyme Corporation · Active, not recruiting · NCT06111586 - A phase 2A multicenter randomized doubleblind placebocontrolled study to evaluate the safety and efficacy of pfizers subtypeselective jak inhibitors for preservation of pancreatic beta cell activity in newly diagnosed…
Pfizer Inc. - Teplizumab in Pediatric Stage 2 Type 1 Diabetes
Sanofi US Services Inc. · Completed · NCT05757713
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.